Gene therapy of genetic diseases and cancer

Pediatric Transplantation

Volumn 3, Issue SUPPL. 1, 1999, Pages 116-121

  McIvor, R Scott ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Gene transfer; Hematopoetic stem cells; Retrovial vectors dihydrofolate eductase

Indexed keywords

ADENOSINE DEAMINASE; DIHYDROFOLATE REDUCTASE; VIRUS VECTOR;

CANCER THERAPY; CHRONIC GRANULOMATOUS DISEASE; CONFERENCE PAPER; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC DISORDER; HEMATOPOIETIC STEM CELL; HUMAN; RETROVIRUS; TUMOR SUPPRESSOR GENE;

CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; FEMALE; FOLLOW-UP STUDIES; FORECASTING; GENE THERAPY; GENETIC DISEASES, INBORN; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; NEOPLASMS;

EID: 0032725925     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3046.1999.00050.x     Document Type: Conference Paper

References (41)

1. FRIEDMANN T, ROBLIN R. Gene therapy for human genetic disease? Science 1972: 175: 949-955.
2. ROSENBERG SA, BLAESE RM, BRENNER MK, DEISSEROTH AB, et al. Human gene marker/therapy clinical protocols. 1998 Hum Gene Ther 1998: 9: 935-976.
3. KARLSSON S. Treatment of genetic defects in hematopoietic cell function by gene transfer. Blood 1991: 78: 2481-2492.
4. GROSSMAN M, RAPER SE, KOZARSKY K, STEIN EA, et al. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet 1994: 6: 335-341.
5. ALTON EW, GEDDES DM, GILL DR, HIGGINS CF, et al. Towards gene therapy for cystic fibrosis: a clinical progress report. Gene Ther 1998: 5: 291-292.
6. MILLER AD. Retroviral vectors. Curr Topics Microbiol Immunol 1992: 158: 1-24.
7. MALECH HL, MAPLES PB, WHITING-THEOBALD N, LINTON GF, et al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci USA 1997: 94: 12133-12138.
8. BARRANGER JA, RICE E, SANSIERI C, BAHNSON A, et al. Transfer of the glucocerebrosidase gene to CD34 cells and their autologous transplantation in patients with Gaucher disease. Blood 1977: 90: 405a.
9. + cells from patients with Gaucher disease: results from a clinical trial. Blood 1997: 90: 237a.
10. COWAN MJ. Bone marrow transplantation for the treatment of genetic diseases. Clin Biochem 1991: 24: 375-381.
11. BRAUN SE, ARONOVICH EL, ANDERSON RA, CROTTY PL, et al. Metabolic correction and cross-correction of mucopolysaccharidosis type II (Hunter syndrome) by retroviral-mediated gene transfer and expression of human iduronate-2-sulfatase. Proc Natl Acad Sci USA 1993: 90: 11830-11834.
12. CARREAU M, BUCHWALD M. The Fanconi anemia genes. Curr Opin Pediatr 1998: 10: 65-69.
13. KREDICH NM, HERSHFIELD MS. Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency. In: SCRIVER CR, BEAUDET AL, SLY WS, VALLE D, eds. The Metabolic Basis of Inherited Disease. New York: McGraw-Hill, 1989. pp. 1045-1075.
14. BLAESE RM, CULVER KW, MILLER AD, CARTER CS, et al. T lymphocyte-directed gene therapy for ADA- SCID. initial trial results after 4 years. Science 1995: 270: 475-480.
15. BORDIGNON C, NOTARANGELO LD, NOBILI N, FERRARI G, et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 1995: 270: 470-475.
16. KOHN DB, WEINBERG KI, NOLTA JA, HEISS LN, et al. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat Med 1995: 1: 1017-1023.
17. + cells. Blood 1977: 90: 404a.
18. MARKERT ML. Purine nucleoside phosphorylase deficiency. Immunodeficiency Rev 1991: 3: 45-81.
19. FORESMAN MD, NELSON DM, MCIVOR RS. Correction of purine nucleoside phosphorylase deficiency by retroviral-mediated gene transfer in mouse S49 T cell lymphoma: a model for gene therapy of T cell immunodeficiency. Hum Gene Ther 1992: 3: 625-631.
20. NELSON DM, BUTTERS KA, MARKERT ML, REINSMOEN NL, et al. Correction of proliferative responses in purine nucleoside phosphorylase (PNP)-deficient T lymphocytes by retroviral-mediated PNP gene transfer and expression. J Immunol 1995: 154: 3006-3014.
21. PARDOLL DM. Cancer vaccines. Nat Med 1998: 4: 525-531.
22. CULVER KW, RAM Z, WALLBRIDGE S, ISHII H, et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992: 256: 1550-1552.
23. HIRSCHCWITZ EA, OHWADA A, PASCAL WR, RUSSI TJ, et al. In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hum Gene Ther 1995: 6: 1055-1063.
24. WOHLHUETER RM, MCIVOR RS, PLAGEMANN PGW. Facilitated transport of uracil and 5-Fluorouracil and permeation of orotic acid into cultured mammalian cells. J Cell Physiol 1980: 104: 309.
25. LICHT T, GOTTESMAN MM, PASTAN I. Transfer of the MDR1 (multidrug resistance) gene: protection of hematopoietic cells from cytotoxic chemotherapy, and selection of transduced cells in vivo. Cytokines Mol Ther 1995: 1: 11-20.
26. HANANIA EG, GILES RE, KAVANAGH J, FU SQ, et al. Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. Proc Natl Acad Sci USA 1996: 93: 15346-15351.
27. MAZE R, HANENBERG H, WILLIAMS DA. Establishing chemoresistance in hematopoietic progenitor cells. Mol Med Today 1997: 3: 350-358.
28. CHU E, ALLEGRA CJ. Antifolates, In: CHABNER BA, LONGO DL, eds. Cancer Chemotherapy and Biotherapy. Philadelphia, Pennsylvania: Lippincott-Raven, 1996. p. 109.
29. MCIVOR RS. Drug-resistant dihydrofolate reductases: generation, expression and therapeutic application. Bone Marrow Transplant 1996: 18: S50-S54.
30. MAY C, GUNTHER R, MCIVOR RS. Protection of mice from lethal doses of methotrexate by transplantation with transgenic bone marrow expressing drug-resistant dihydrofolate reductase activity. Blood 1995: 86: 2439-2448.
31. MCIVOR RS, ZIMMERMAN CK, BOELK-GALVAN D, VAGT MD, BELUR L. Methotrexate is not eliminated more rapidly in animals rendered drug-resistant by transplantation with marrow expressing drug-resistant dihydrofolate reductase (DHFR) activity. Abstr Ann Mtg Am Soc Gene Therapy 1998: 11.
32. JAMES RI, MAY C, VAGT MD, STUDEBAKER R, et al. Transgenic mice expressing the Tyr22 variant of murine DHFR; protection of transgenic marrow transplant recipients from lethal doses of methotrexate. Exp Hematol 1997: 25: 1286.
33. ZHAO R, MCIVOR RS, GRIFFIN JD, VERFAILLIE CM. Gene therapy for CML. A retroviral vector that renders hematopoietic progenitors methotrexate resistant and CML progenitors functionally normal and non-tumorigenic in vivo. Blood 1997: 90: 4687-4698.
34. BCR/ABL gene of the Philadelphia chromosome. Science 1990: 247: 824.
35. DUNBAR CE, EMMONS RVB. Gene transfer into hematopoietic progenitor and stem cells. Prog Problems Stem Cells 1994: 12: 563.
36. MUZYCZKA N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Topics Microbiol Immunol 1992: 158: 97-129.
37. NALDINI L, BLOMER U, GALLAY P, ORY D, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996: 272: 195.
38. JAMES RI, MAY C, VAGT M, MCIVOR RS. Selective engraftment of transgenic marrow stem cells expressing methotrexate-resistant dihydrofolate reductase. Abstr. Cold Spring Harbor Conf. on Gene Therapy 1996: 139.
39. PAN D, ARONOVICH EL, MCIVOR RS, WHITLEY CB. Retrovirus vector studies toward stem cell gene therapy for mucopolysaccharidosis type I. Am J Hum Genet 1995: 57: A248.
40. BUI TH, JONES DR. Stem cell transplantation into the fetal recipient: challenges and prospects. Curr Opin Obstet Gynecol 1998: 10: 105-108.
41. WADMAN M. Germline gene therapy 'must be spared excessive regulation'. Nature 1998: 392: 317.